Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.
Costa
Daniel B
DB
Schumer
Susan T
ST
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D018450:Disease Progression; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D011799:Quinazolines / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors
D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib